No Data
Individual Investors Are INKON Life Technology Co., Ltd.'s (SZSE:300143) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥874m Last Week
Inkon Life Technology (300143.SZ): The companies invested by the company do not involve cell immunotherapy business.
On September 9th, Yinkang Life Technology (300143.SZ) stated on the investor interaction platform that the invested companies are not involved in this business (cellular immunotherapy).
INKON Life Technology: Half-year report for the year 2024.
INKON Life Technology: Summary of Half-Year Report in 2024.
Inkon life technology (300143.SZ): net income in the first half of the year was 54.8011 million yuan, a year-on-year decrease of 22.44%
In August 22th, 2024, Inkon Life Technology (300143.SZ) announced its semi-annual report for the year, with revenue of 0.823 billion yuan, a year-on-year increase of 13.74%; net income attributable to shareholders of the listed company of 54.8011 million yuan, a year-on-year decrease of 22.44%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 50.8226 million yuan, a year-on-year decrease of 24.34%; basic earnings per share of 0.0860 yuan.
Inkon Life Technology (300143.SZ): The shareholding period of the controlling shareholder has passed halfway, with a cumulative increase of 5.6334 million shares.
On July 29th, Gelunhui reported that Inkon Life Technology (300143.SZ) announced that the shareholding plan of its controlling shareholder, Inkon Medical Investment, has passed its implementation period as of July 29th, 2024. Since the date of the plan's announcement until July 29th, 2024, Inkon Medical Investment has cumulatively increased its shareholding in the company by 5.6334 million shares, accounting for 0.89% of the company's current total share capital, and the increase amount is 44.6737 million yuan through the concentrated bidding trading system of the Shenzhen Stock Exchange. The shareholding plan has not yet been completed, and Inkon Medical Investment will continue to increase its shareholding in the company in accordance with the plan.
No Data
